Literature DB >> 15148489

Significance of selectively targeted apoptotic rete cells in graft-versus-host disease.

George F Murphy1, Robert Korngold.   

Abstract

Considerable data exist regarding the mechanisms of allostimulation and homing (the effector phases) in graft-versus-host disease (GVHD). Current dogma suggests that target specificity involves preferential injury to epithelial surfaces of the skin and squamous mucosae, liver, and gut. Little attention has been devoted, however, to mechanisms of cellular targeting or to whether heterogeneity exists in target tissues with regard to a threshold for cellular injury. A recent breakthrough in understanding the target stage of GVHD indicates that the predominant pathway of injury to squamous epithelial cells involves apoptosis. Moreover, apoptotic injury may be associated or unassociated with local T-cell infiltration and involves phenotypically and antigenically distinctive epithelial cells within the basal layer of the skin and squamous mucosa. These cells are confined to rete ridges in the skin and retelike prominences in the dorsal tongue and are designated as selectively targeted apoptotic rete (STAR) cells. The discovery of STAR cells in GVHD paves the way for speculation and experimentation to determine why these subpopulations are selectively vulnerable and how soluble and cellular effectors of apoptosis contribute to their ultimate demise. Novel approaches to GVHD treatment derived from understanding mechanisms of selective epithelial injury are likely to use strategies to render target cells less susceptible to the apoptosis that is ultimately responsible for organ dysfunction and failure. Copyright 2004 American Society for Blood and Marrow Transplantation

Entities:  

Mesh:

Year:  2004        PMID: 15148489     DOI: 10.1016/j.bbmt.2004.02.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  6 in total

1.  Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models.

Authors:  D Kim; H-H Won; S Su; L Cheng; W Xu; N Hamad; J Uhm; V Gupta; J Kuruvilla; H A Messner; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2014-03-03       Impact factor: 5.483

Review 2.  Target cells in graft-versus-host disease: implications for cancer therapy.

Authors:  George F Murphy
Journal:  Clin Rev Allergy Immunol       Date:  2007-08-14       Impact factor: 8.667

3.  The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality.

Authors:  Kai Sun; Minghui Li; Marina Konopleva; Sergej Konoplev; L Clifton Stephens; Steven M Kornblau; Olga Frolova; Danice E C Wilkins; Weihong Ma; Lisbeth A Welniak; Michael Andreeff; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2007-02-26       Impact factor: 5.742

4.  Immunohistopathological characterization and the impact of topical immunomodulatory therapy in oral chronic graft-versus-host disease: A pilot study.

Authors:  Acf Motta; Q Zhan; A Larson; M Lerman; S-B Woo; R J Soiffer; G F Murphy; N S Treister
Journal:  Oral Dis       Date:  2018-03-13       Impact factor: 3.511

5.  Aberrant HLA-DR expression in the conjunctival epithelium after autologous serum treatment in patients with graft-versus-host disease or Sjögren's syndrome.

Authors:  Katerina Jirsova; Petra Seidler Stangova; Michalis Palos; Gabriela Mahelkova; Sarka Kalasova; Ivana Rybickova; Tor Paaske Utheim; Viera Vesela
Journal:  PLoS One       Date:  2020-04-21       Impact factor: 3.240

Review 6.  Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease.

Authors:  Pedro Santos E Sousa; Clare L Bennett; Ronjon Chakraverty
Journal:  Front Immunol       Date:  2018-05-02       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.